CU
CUE.AX
—
ASX
Pharmaceuticals & Medical Research
Cue.Ax
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
5,56 %
Op margin
35,8 %
ROE
10,9 %
Net margin
11,5 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
CUE.AX is an oil and gas exploration and production company operating in the Energy - Fossil Fuels sector.
Business. Cue Biopharma Inc (CUE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target120,00
Analyst recommendations
1 analysts · consensus BuyBuy1
Hold0
Sell0
12-month price target
120,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership
—
not yet wired
Profitability→
10,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CUE.AX. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Cue Biopharma Inc (CUE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDCUE.AX maintains a strong liquidity position, with a current ratio of 2.53, indicating the company can cover its short-term liabilities more than twice over with its current assets. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of AUD 10.83 million and a free cash flow of AUD -14.11 million, which suggests that while the company is investing heavily in operations, it still retains a solid cash buffer.
In terms of profitability, CUE.AX reports a return on equity (ROE) of 10.88% and a return on assets (ROA) of 5.56%, both of which are strong indicators of efficient capital use and asset management. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key performance indicators for evaluating the effectiveness of capital deployment in the oil and gas sector.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher operational and market risks, particularly in the volatile oil and gas industry.
CUE.AX is currently experiencing a growth trajectory, with a free cash flow of AUD -14.11 million and a capital expenditure of AUD -15.38 million, indicating significant investment in the business. The company's outlook for the current fiscal year suggests continued investment, with no immediate signs of a slowdown in capital spending or a shift in strategic direction.
The risk assessment for CUE.AX indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no long-term debt obligations, which further supports the low risk profile.
Recent events and filings for CUE.AX do not indicate any material changes in the company's operations or financial position. The company has not issued any new shares or announced any significant capital raising activities in the latest available data.
Key takeaways
- CUE.AX has a strong liquidity position with a current ratio of 2.53.
- The company's ROE of 10.88% and ROA of 5.56% indicate efficient capital use.
- CUE.AX is investing heavily in capital expenditures, with a free cash flow of AUD -14.11 million.
- The company has a low risk profile, with no immediate liquidity or dilution flags.
- CUE.AX's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
A$0,13
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
A$58.1M
Net cashⓘ
A$10.6M
Current ratioⓘ
2.5
Debt / equityⓘ
0.0
ROAⓘ
5.6%
ROEⓘ
10.9%
Cash conversionⓘ
377.0%
CapEx / revenueⓘ
-28.1%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs CUE · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+141,1 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+52,8 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-59,6 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+105,7 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+119,6 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+43,1 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-17,40
Predicted surprise
+0,00
Beat probability
45 %
Analysts
1
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
LowA$120,00
MeanA$120,00
MedianA$120,00
HighA$120,00
SpotA$0,13
+94388.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin35,9 %Above P75
Net Margin11,5 %Above P75
ROE10,9 %Above P75
Capex / Rev-28,1 %Bottom quartile
D/E0,00Above median
Cash Conv3,77Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 3 641 085 sh17 grants13 insiders
- Director, Chief Executive Officer · Common Stock Warrants (Right to Buy) → Common StockAcquired 45 453 @ $11,00purchase · 2026-06-01
- Director, Chief Executive Officer · Pre-Funded Warrants (Right to Buy) → Common StockAcquired 90 906 @ $0,00purchase · 2026-06-01
- Director · Stock Option (Right to Buy) → Common StockAcquired 1 626 @ $21,90grant · 2026-05-30
- Director · Stock Option (Right to Buy) → Common StockAcquired 1 626 @ $21,90grant · 2026-05-30
- Director, CHIEF EXECUTIVE OFFICER · Stock Option (right to buy) → Common StockAcquired 655 074 @ $30,42grant · 2026-05-03
- SVP, GENERAL COUNSEL · Stock Option (right to buy) → Common StockAcquired 200 000 @ $0,29grant · 2026-04-09
- CHIEF BUSINESS OFFICER · Stock Option (right to buy) → Common StockAcquired 250 000 @ $0,29grant · 2026-04-09
- CHIEF DEVELOPMENT OFFICER · Stock Option (right to buy) → Common StockAcquired 100 000 @ $0,29grant · 2026-04-09
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 24 400 @ $0,34grant · 2026-01-02
- SVP, GENERAL COUNSEL · Stock Option (right to buy) → Common StockAcquired 70 000 @ $0,70grant · 2025-12-03
- Director, CHIEF EXECUTIVE OFFICER · Stock Option (right to buy) → Common StockAcquired 1 875 000 @ $0,72grant · 2025-09-29
- CHIEF DEVELOPMENT OFFICER · Stock Option (right to buy) → Common StockAcquired 50 000 @ $0,72grant · 2025-09-29
- CHIEF BUSINESS OFFICER · Stock Option (right to buy) → Common StockAcquired 125 000 @ $0,72grant · 2025-09-29
- SVP, GENERAL COUNSEL · Stock Option (right to buy) → Common StockAcquired 30 000 @ $0,70grant · 2025-09-26
Physical assets
1 tracked| Asset | Type | Commodity | Country | Role |
|---|---|---|---|---|
| Maari Oil and Gas Field (New Zealand) | Oil gas extraction | Oil And Gas | New Zealand | Parent |
Tracked physical assets associated with this issuer (operated, managed, or owned).
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- CUE.AX Market data — financials · 2026-05-27
Ownership & reference
Insider activity
Net buying5 buys · 0 sellsnet $100K2 insiders · last 365d
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 327 537 · 2026-05-03
- Director · Common StockBought 86 947 @ $0,32$28K · 2025-12-30
- Director · Common StockBought 4 229 @ $0,31$1K · 2025-12-30
- Director · Common StockBought 78 116 @ $0,31$24K · 2025-12-30
- Director · Common StockBought 77 417 @ $0,30$23K · 2025-12-30
- Director · Common StockBought 77 148 @ $0,30$23K · 2025-12-30
Short positioning
307.9Kshares short+3.3% vs prior
2.22days to cover
49.6%short of daily vol
1.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CUE.AXCanonical
ASX · AUD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 2.74xDerived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 40.3%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 168.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 61.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 61.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 7.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 31.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 51.0%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 195.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 4.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 34.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 20.8%Derived (calculated)
- Net margin (FY 2025-12-31): -96.9%Derived (calculated)
- Return on equity (FY 2025-12-31): -100.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -63.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.60xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 36.0%Derived (calculated)
- Capex (annual): USD 177KSEC XBRL filing
- Cash & equivalents (annual): USD 27.14MSEC XBRL filing
- Operating income (annual): USD -26.55MSEC XBRL filing
- Total operating expenses (annual): USD 54.02MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Revenue (annual): USD 27.47MSEC XBRL filing
- Net income (annual): USD -26.6MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-01 00:00 UTCINSIDER2 insider transactions — 2026-06 2 derivative
2026-06-01INSIDERLin Shao-Lee acquired 45.5k sh Common Stock Warrants (Right to Buy) — Director, Chief Executive Officer
2026-06-01INSIDERLin Shao-Lee acquired 90.9k sh Pre-Funded Warrants (Right to Buy) — Director, Chief Executive Officer
2026-05-30 00:00 UTCINSIDER4 insider transactions — 2026-05 3 derivative
2026-05-30INSIDERMeehan Viola Mong acquired 1.6k sh Stock Option (Right to Buy) — Director
2026-05-30INSIDERCamardo Daniel A. acquired 1.6k sh Stock Option (Right to Buy) — Director
2026-05-03INSIDERLin Shao-Lee transacted 327.5k sh — Director, CHIEF EXECUTIVE OFFICER
2026-05-03INSIDERLin Shao-Lee acquired 655.1k sh Stock Option (right to buy) — Director, CHIEF EXECUTIVE OFFICER
2026-04-09 00:00 UTCINSIDER3 insider transactions — 2026-04 3 derivative
2026-04-09INSIDERSandercock Colin acquired 200.0k sh Stock Option (right to buy) — SVP, GENERAL COUNSEL
2026-04-09INSIDERWarren Lucinda acquired 250.0k sh Stock Option (right to buy) — CHIEF BUSINESS OFFICER
2026-04-09INSIDERBaker Daniel G. acquired 100.0k sh Stock Option (right to buy) — CHIEF DEVELOPMENT OFFICER
2026-01-02 00:00 UTCINSIDER6 insider transactions — 2026-01 6 derivative
2026-01-02INSIDERBroadfoot Jill Marie acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERKiener Peter A acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERGarzone Pamela acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERMorich Frank acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERVerheyen Patrick acquired 24.4k sh Stock Option (right to buy) — Director
2026-01-02INSIDERSarraf Pasha acquired 24.4k sh Stock Option (right to buy) — Director
2025-12-30 00:00 UTCINSIDER6 insider transactions — 2025-12 1 derivative
2025-12-30INSIDERSarraf Pasha bought 86.9k sh — Director ~$28k
2025-12-30INSIDERSarraf Pasha bought 4.2k sh — Director ~$1k
2025-12-30INSIDERSarraf Pasha bought 78.1k sh — Director ~$24k
2025-12-30INSIDERSarraf Pasha bought 77.4k sh — Director ~$23k
2025-12-30INSIDERSarraf Pasha bought 77.1k sh — Director ~$23k
2025-12-03INSIDERSandercock Colin acquired 70.0k sh Stock Option (right to buy) — SVP, GENERAL COUNSEL
Showing the 40 most recent of 46 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage